Neoantigen vaccine spurs immune response in glioblastoma
Glioblastoma is termed an immunologically ‘cold’ tumor – a disadvantage for treatment with immunotherapy – because the brain tumor contains very few immune cells that are required to generate an immune response against the tumor.
In a report, scientists at Dana-Farber Cancer Institute say they have shown that a personalized ‘neoantigen’ vaccine can spur a response against glioblastoma, with immune T-cells generated by the vaccine migrating into the brain tumor, creating a ‘hotter,’ inflamed environment around the cancer cells. The neoantigen vaccine approach has been pioneered in the laboratory of Catherine Wu, MD, at Dana-Farber.
“This is the first time it has been shown that a vaccine can generate immune cells against the tumor that can traffic from the bloodstream into a glioblastoma tumor,” said David Reardon, MD, senior author of the study. Reardon is clinical director of the Center for Neuro-Oncology at Dana-Farber.
Click here to read more.
2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.
2019 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 28-31, 2019; Orlando, Fla.
Sept. 8-11, 2019; Leuven, Belgium
2019 WFNS Special World Congress
Sept. 9-12, 2019; Beijing
18th Congress of International Society of Craniofacial Surgery
Sept. 16-19, 2019; Paris